ROLE OF BLOOD PRESSURE REDUCTION IN PREVENTION OF CARDIAC AND VASCULAR HYPERTROPHY

We investigated whether prevention of cardiac and vascular remodelling associated with inhibition of angiotensin II is independent of the blood pressure (BP) lowering action of angiotensin II type 1 (AT1) receptor blockade. Spontaneously hypertensive rats, 8 weeks old, were treated with olmesartan,...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	H. Yokoyama [verfasserIn] D. B. Averill [verfasserIn] K. B. Brosnihan [verfasserIn] R. D. Smith [verfasserIn] E. L. Schiffrin [verfasserIn] C. M. Ferrario [verfasserIn]

Format:	E-Artikel
Sprache:	Russisch

Erschienen:	2011

Schlagwörter:	atenolol cardiac hypertrophy hypertension olmesartan vascular remodelling

Übergeordnetes Werk:	In: Российский кардиологический журнал - «FIRMA «SILICEA» LLC, 2019, (2011), 4, Seite 102-108
Übergeordnetes Werk:	year:2011 ; number:4 ; pages:102-108

Links:	Link aufrufen Link aufrufen Journal toc Journal toc

Katalog-ID:	DOAJ029443288

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ029443288
003	DE-627
005	20230501192743.0
007	cr uuu---uuuuu
008	230226s2011 xx \|\|\|\|\|o 00\| \|\|rus c
035			\|a (DE-627)DOAJ029443288
035			\|a (DE-599)DOAJ4b28ca57c7d64d6d819d4d1f90ad857e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a rus
050		0	\|a RC666-701
100	0		\|a H. Yokoyama \|e verfasserin \|4 aut
245	1	0	\|a ROLE OF BLOOD PRESSURE REDUCTION IN PREVENTION OF CARDIAC AND VASCULAR HYPERTROPHY
264		1	\|c 2011
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a We investigated whether prevention of cardiac and vascular remodelling associated with inhibition of angiotensin II is independent of the blood pressure (BP) lowering action of angiotensin II type 1 (AT1) receptor blockade. Spontaneously hypertensive rats, 8 weeks old, were treated with olmesartan, atenolol, or vehicle in their drinking water for 56 days. At the end of each treatment, arterial pressure and heart rate were measured, the ratio of heart weight to body weight was calculated, collagen deposition in the heart was determined histochemically using picrosirius red staining, and wall-to-lumen ratio in isolated mesenteric arteries was measured by a video graphic approach. At 3 weeks after the initiation of treatment, rats medicated with olmesartan showed lower values of systolic BP compared with rats given atenolol or vehicle, whereas no difference in directly measured BP were observed at the end of study in anesthetized rats given olmesartan or atenolol. Rats given atenolol showed sustained bradycardia, whereas cardiac hypertrophy and collagen deposition was prevented only in spontaneously hypertensive rats given olmesartan. Olmesartan or atenolol reduced arteriolar wall-to-lumen ratio (olmesartan: 11,5±0,4%; atenolol: 13,3±0,6%; vehicle: 18,4%±1,1); however, this effect was greatest in rats medicated with the angiotensin II type 1 antagonist. Although control of BP is a factor in the prevention of cardiac and vascular hypertrophy, our studies suggest that blockade of angiotensin II receptors may attenuate the structural changes in the heart and blood vessels of hypertensive animals independent of a reduction in BP.
650		4	\|a atenolol
650		4	\|a cardiac hypertrophy
650		4	\|a hypertension
650		4	\|a olmesartan
650		4	\|a vascular remodelling
653		0	\|a Diseases of the circulatory (Cardiovascular) system
700	0		\|a D. B. Averill \|e verfasserin \|4 aut
700	0		\|a K. B. Brosnihan \|e verfasserin \|4 aut
700	0		\|a R. D. Smith \|e verfasserin \|4 aut
700	0		\|a E. L. Schiffrin \|e verfasserin \|4 aut
700	0		\|a C. M. Ferrario \|e verfasserin \|4 aut
773	0	8	\|i In \|t Российский кардиологический журнал \|d «FIRMA «SILICEA» LLC, 2019 \|g (2011), 4, Seite 102-108 \|w (DE-627)1760594547 \|x 26187620 \|7 nnns
773	1	8	\|g year:2011 \|g number:4 \|g pages:102-108
856	4	0	\|u https://doaj.org/article/4b28ca57c7d64d6d819d4d1f90ad857e \|z kostenfrei
856	4	0	\|u https://russjcardiol.elpub.ru/jour/article/view/1131 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1560-4071 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2618-7620 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a SSG-OLC-PHA
951			\|a AR
952			\|j 2011 \|e 4 \|h 102-108

Indexfelder

author_variant	h y hy d b a dba k b b kbb r d s rds e l s els c m f cmf
matchkey_str	article:26187620:2011----::oeflopesrrdcinnrvninfadaa
hierarchy_sort_str	2011
callnumber-subject-code	RC
publishDate	2011
allfields	(DE-627)DOAJ029443288 (DE-599)DOAJ4b28ca57c7d64d6d819d4d1f90ad857e DE-627 ger DE-627 rakwb rus RC666-701 H. Yokoyama verfasserin aut ROLE OF BLOOD PRESSURE REDUCTION IN PREVENTION OF CARDIAC AND VASCULAR HYPERTROPHY 2011 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier We investigated whether prevention of cardiac and vascular remodelling associated with inhibition of angiotensin II is independent of the blood pressure (BP) lowering action of angiotensin II type 1 (AT1) receptor blockade. Spontaneously hypertensive rats, 8 weeks old, were treated with olmesartan, atenolol, or vehicle in their drinking water for 56 days. At the end of each treatment, arterial pressure and heart rate were measured, the ratio of heart weight to body weight was calculated, collagen deposition in the heart was determined histochemically using picrosirius red staining, and wall-to-lumen ratio in isolated mesenteric arteries was measured by a video graphic approach. At 3 weeks after the initiation of treatment, rats medicated with olmesartan showed lower values of systolic BP compared with rats given atenolol or vehicle, whereas no difference in directly measured BP were observed at the end of study in anesthetized rats given olmesartan or atenolol. Rats given atenolol showed sustained bradycardia, whereas cardiac hypertrophy and collagen deposition was prevented only in spontaneously hypertensive rats given olmesartan. Olmesartan or atenolol reduced arteriolar wall-to-lumen ratio (olmesartan: 11,5±0,4%; atenolol: 13,3±0,6%; vehicle: 18,4%±1,1); however, this effect was greatest in rats medicated with the angiotensin II type 1 antagonist. Although control of BP is a factor in the prevention of cardiac and vascular hypertrophy, our studies suggest that blockade of angiotensin II receptors may attenuate the structural changes in the heart and blood vessels of hypertensive animals independent of a reduction in BP. atenolol cardiac hypertrophy hypertension olmesartan vascular remodelling Diseases of the circulatory (Cardiovascular) system D. B. Averill verfasserin aut K. B. Brosnihan verfasserin aut R. D. Smith verfasserin aut E. L. Schiffrin verfasserin aut C. M. Ferrario verfasserin aut In Российский кардиологический журнал «FIRMA «SILICEA» LLC, 2019 (2011), 4, Seite 102-108 (DE-627)1760594547 26187620 nnns year:2011 number:4 pages:102-108 https://doaj.org/article/4b28ca57c7d64d6d819d4d1f90ad857e kostenfrei https://russjcardiol.elpub.ru/jour/article/view/1131 kostenfrei https://doaj.org/toc/1560-4071 Journal toc kostenfrei https://doaj.org/toc/2618-7620 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 2011 4 102-108
spelling	(DE-627)DOAJ029443288 (DE-599)DOAJ4b28ca57c7d64d6d819d4d1f90ad857e DE-627 ger DE-627 rakwb rus RC666-701 H. Yokoyama verfasserin aut ROLE OF BLOOD PRESSURE REDUCTION IN PREVENTION OF CARDIAC AND VASCULAR HYPERTROPHY 2011 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier We investigated whether prevention of cardiac and vascular remodelling associated with inhibition of angiotensin II is independent of the blood pressure (BP) lowering action of angiotensin II type 1 (AT1) receptor blockade. Spontaneously hypertensive rats, 8 weeks old, were treated with olmesartan, atenolol, or vehicle in their drinking water for 56 days. At the end of each treatment, arterial pressure and heart rate were measured, the ratio of heart weight to body weight was calculated, collagen deposition in the heart was determined histochemically using picrosirius red staining, and wall-to-lumen ratio in isolated mesenteric arteries was measured by a video graphic approach. At 3 weeks after the initiation of treatment, rats medicated with olmesartan showed lower values of systolic BP compared with rats given atenolol or vehicle, whereas no difference in directly measured BP were observed at the end of study in anesthetized rats given olmesartan or atenolol. Rats given atenolol showed sustained bradycardia, whereas cardiac hypertrophy and collagen deposition was prevented only in spontaneously hypertensive rats given olmesartan. Olmesartan or atenolol reduced arteriolar wall-to-lumen ratio (olmesartan: 11,5±0,4%; atenolol: 13,3±0,6%; vehicle: 18,4%±1,1); however, this effect was greatest in rats medicated with the angiotensin II type 1 antagonist. Although control of BP is a factor in the prevention of cardiac and vascular hypertrophy, our studies suggest that blockade of angiotensin II receptors may attenuate the structural changes in the heart and blood vessels of hypertensive animals independent of a reduction in BP. atenolol cardiac hypertrophy hypertension olmesartan vascular remodelling Diseases of the circulatory (Cardiovascular) system D. B. Averill verfasserin aut K. B. Brosnihan verfasserin aut R. D. Smith verfasserin aut E. L. Schiffrin verfasserin aut C. M. Ferrario verfasserin aut In Российский кардиологический журнал «FIRMA «SILICEA» LLC, 2019 (2011), 4, Seite 102-108 (DE-627)1760594547 26187620 nnns year:2011 number:4 pages:102-108 https://doaj.org/article/4b28ca57c7d64d6d819d4d1f90ad857e kostenfrei https://russjcardiol.elpub.ru/jour/article/view/1131 kostenfrei https://doaj.org/toc/1560-4071 Journal toc kostenfrei https://doaj.org/toc/2618-7620 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 2011 4 102-108
allfields_unstemmed	(DE-627)DOAJ029443288 (DE-599)DOAJ4b28ca57c7d64d6d819d4d1f90ad857e DE-627 ger DE-627 rakwb rus RC666-701 H. Yokoyama verfasserin aut ROLE OF BLOOD PRESSURE REDUCTION IN PREVENTION OF CARDIAC AND VASCULAR HYPERTROPHY 2011 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier We investigated whether prevention of cardiac and vascular remodelling associated with inhibition of angiotensin II is independent of the blood pressure (BP) lowering action of angiotensin II type 1 (AT1) receptor blockade. Spontaneously hypertensive rats, 8 weeks old, were treated with olmesartan, atenolol, or vehicle in their drinking water for 56 days. At the end of each treatment, arterial pressure and heart rate were measured, the ratio of heart weight to body weight was calculated, collagen deposition in the heart was determined histochemically using picrosirius red staining, and wall-to-lumen ratio in isolated mesenteric arteries was measured by a video graphic approach. At 3 weeks after the initiation of treatment, rats medicated with olmesartan showed lower values of systolic BP compared with rats given atenolol or vehicle, whereas no difference in directly measured BP were observed at the end of study in anesthetized rats given olmesartan or atenolol. Rats given atenolol showed sustained bradycardia, whereas cardiac hypertrophy and collagen deposition was prevented only in spontaneously hypertensive rats given olmesartan. Olmesartan or atenolol reduced arteriolar wall-to-lumen ratio (olmesartan: 11,5±0,4%; atenolol: 13,3±0,6%; vehicle: 18,4%±1,1); however, this effect was greatest in rats medicated with the angiotensin II type 1 antagonist. Although control of BP is a factor in the prevention of cardiac and vascular hypertrophy, our studies suggest that blockade of angiotensin II receptors may attenuate the structural changes in the heart and blood vessels of hypertensive animals independent of a reduction in BP. atenolol cardiac hypertrophy hypertension olmesartan vascular remodelling Diseases of the circulatory (Cardiovascular) system D. B. Averill verfasserin aut K. B. Brosnihan verfasserin aut R. D. Smith verfasserin aut E. L. Schiffrin verfasserin aut C. M. Ferrario verfasserin aut In Российский кардиологический журнал «FIRMA «SILICEA» LLC, 2019 (2011), 4, Seite 102-108 (DE-627)1760594547 26187620 nnns year:2011 number:4 pages:102-108 https://doaj.org/article/4b28ca57c7d64d6d819d4d1f90ad857e kostenfrei https://russjcardiol.elpub.ru/jour/article/view/1131 kostenfrei https://doaj.org/toc/1560-4071 Journal toc kostenfrei https://doaj.org/toc/2618-7620 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 2011 4 102-108
allfieldsGer	(DE-627)DOAJ029443288 (DE-599)DOAJ4b28ca57c7d64d6d819d4d1f90ad857e DE-627 ger DE-627 rakwb rus RC666-701 H. Yokoyama verfasserin aut ROLE OF BLOOD PRESSURE REDUCTION IN PREVENTION OF CARDIAC AND VASCULAR HYPERTROPHY 2011 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier We investigated whether prevention of cardiac and vascular remodelling associated with inhibition of angiotensin II is independent of the blood pressure (BP) lowering action of angiotensin II type 1 (AT1) receptor blockade. Spontaneously hypertensive rats, 8 weeks old, were treated with olmesartan, atenolol, or vehicle in their drinking water for 56 days. At the end of each treatment, arterial pressure and heart rate were measured, the ratio of heart weight to body weight was calculated, collagen deposition in the heart was determined histochemically using picrosirius red staining, and wall-to-lumen ratio in isolated mesenteric arteries was measured by a video graphic approach. At 3 weeks after the initiation of treatment, rats medicated with olmesartan showed lower values of systolic BP compared with rats given atenolol or vehicle, whereas no difference in directly measured BP were observed at the end of study in anesthetized rats given olmesartan or atenolol. Rats given atenolol showed sustained bradycardia, whereas cardiac hypertrophy and collagen deposition was prevented only in spontaneously hypertensive rats given olmesartan. Olmesartan or atenolol reduced arteriolar wall-to-lumen ratio (olmesartan: 11,5±0,4%; atenolol: 13,3±0,6%; vehicle: 18,4%±1,1); however, this effect was greatest in rats medicated with the angiotensin II type 1 antagonist. Although control of BP is a factor in the prevention of cardiac and vascular hypertrophy, our studies suggest that blockade of angiotensin II receptors may attenuate the structural changes in the heart and blood vessels of hypertensive animals independent of a reduction in BP. atenolol cardiac hypertrophy hypertension olmesartan vascular remodelling Diseases of the circulatory (Cardiovascular) system D. B. Averill verfasserin aut K. B. Brosnihan verfasserin aut R. D. Smith verfasserin aut E. L. Schiffrin verfasserin aut C. M. Ferrario verfasserin aut In Российский кардиологический журнал «FIRMA «SILICEA» LLC, 2019 (2011), 4, Seite 102-108 (DE-627)1760594547 26187620 nnns year:2011 number:4 pages:102-108 https://doaj.org/article/4b28ca57c7d64d6d819d4d1f90ad857e kostenfrei https://russjcardiol.elpub.ru/jour/article/view/1131 kostenfrei https://doaj.org/toc/1560-4071 Journal toc kostenfrei https://doaj.org/toc/2618-7620 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 2011 4 102-108
allfieldsSound	(DE-627)DOAJ029443288 (DE-599)DOAJ4b28ca57c7d64d6d819d4d1f90ad857e DE-627 ger DE-627 rakwb rus RC666-701 H. Yokoyama verfasserin aut ROLE OF BLOOD PRESSURE REDUCTION IN PREVENTION OF CARDIAC AND VASCULAR HYPERTROPHY 2011 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier We investigated whether prevention of cardiac and vascular remodelling associated with inhibition of angiotensin II is independent of the blood pressure (BP) lowering action of angiotensin II type 1 (AT1) receptor blockade. Spontaneously hypertensive rats, 8 weeks old, were treated with olmesartan, atenolol, or vehicle in their drinking water for 56 days. At the end of each treatment, arterial pressure and heart rate were measured, the ratio of heart weight to body weight was calculated, collagen deposition in the heart was determined histochemically using picrosirius red staining, and wall-to-lumen ratio in isolated mesenteric arteries was measured by a video graphic approach. At 3 weeks after the initiation of treatment, rats medicated with olmesartan showed lower values of systolic BP compared with rats given atenolol or vehicle, whereas no difference in directly measured BP were observed at the end of study in anesthetized rats given olmesartan or atenolol. Rats given atenolol showed sustained bradycardia, whereas cardiac hypertrophy and collagen deposition was prevented only in spontaneously hypertensive rats given olmesartan. Olmesartan or atenolol reduced arteriolar wall-to-lumen ratio (olmesartan: 11,5±0,4%; atenolol: 13,3±0,6%; vehicle: 18,4%±1,1); however, this effect was greatest in rats medicated with the angiotensin II type 1 antagonist. Although control of BP is a factor in the prevention of cardiac and vascular hypertrophy, our studies suggest that blockade of angiotensin II receptors may attenuate the structural changes in the heart and blood vessels of hypertensive animals independent of a reduction in BP. atenolol cardiac hypertrophy hypertension olmesartan vascular remodelling Diseases of the circulatory (Cardiovascular) system D. B. Averill verfasserin aut K. B. Brosnihan verfasserin aut R. D. Smith verfasserin aut E. L. Schiffrin verfasserin aut C. M. Ferrario verfasserin aut In Российский кардиологический журнал «FIRMA «SILICEA» LLC, 2019 (2011), 4, Seite 102-108 (DE-627)1760594547 26187620 nnns year:2011 number:4 pages:102-108 https://doaj.org/article/4b28ca57c7d64d6d819d4d1f90ad857e kostenfrei https://russjcardiol.elpub.ru/jour/article/view/1131 kostenfrei https://doaj.org/toc/1560-4071 Journal toc kostenfrei https://doaj.org/toc/2618-7620 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 2011 4 102-108
language	Russian
source	In Российский кардиологический журнал (2011), 4, Seite 102-108 year:2011 number:4 pages:102-108
sourceStr	In Российский кардиологический журнал (2011), 4, Seite 102-108 year:2011 number:4 pages:102-108
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	atenolol cardiac hypertrophy hypertension olmesartan vascular remodelling Diseases of the circulatory (Cardiovascular) system
isfreeaccess_bool	true
container_title	Российский кардиологический журнал
authorswithroles_txt_mv	H. Yokoyama @@aut@@ D. B. Averill @@aut@@ K. B. Brosnihan @@aut@@ R. D. Smith @@aut@@ E. L. Schiffrin @@aut@@ C. M. Ferrario @@aut@@
publishDateDaySort_date	2011-01-01T00:00:00Z
hierarchy_top_id	1760594547
id	DOAJ029443288
language_de	russisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ029443288</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230501192743.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2011 xx \|\|\|\|\|o 00\| \|\|rus c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ029443288</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ4b28ca57c7d64d6d819d4d1f90ad857e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">H. Yokoyama</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">ROLE OF BLOOD PRESSURE REDUCTION IN PREVENTION OF CARDIAC AND VASCULAR HYPERTROPHY</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2011</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">We investigated whether prevention of cardiac and vascular remodelling associated with inhibition of angiotensin II is independent of the blood pressure (BP) lowering action of angiotensin II type 1 (AT1) receptor blockade. Spontaneously hypertensive rats, 8 weeks old, were treated with olmesartan, atenolol, or vehicle in their drinking water for 56 days. At the end of each treatment, arterial pressure and heart rate were measured, the ratio of heart weight to body weight was calculated, collagen deposition in the heart was determined histochemically using picrosirius red staining, and wall-to-lumen ratio in isolated mesenteric arteries was measured by a video graphic approach. At 3 weeks after the initiation of treatment, rats medicated with olmesartan showed lower values of systolic BP compared with rats given atenolol or vehicle, whereas no difference in directly measured BP were observed at the end of study in anesthetized rats given olmesartan or atenolol. Rats given atenolol showed sustained bradycardia, whereas cardiac hypertrophy and collagen deposition was prevented only in spontaneously hypertensive rats given olmesartan. Olmesartan or atenolol reduced arteriolar wall-to-lumen ratio (olmesartan: 11,5±0,4%; atenolol: 13,3±0,6%; vehicle: 18,4%±1,1); however, this effect was greatest in rats medicated with the angiotensin II type 1 antagonist. Although control of BP is a factor in the prevention of cardiac and vascular hypertrophy, our studies suggest that blockade of angiotensin II receptors may attenuate the structural changes in the heart and blood vessels of hypertensive animals independent of a reduction in BP.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">atenolol</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cardiac hypertrophy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hypertension</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">olmesartan</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">vascular remodelling</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">D. B. Averill</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">K. B. Brosnihan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">R. D. Smith</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E. L. Schiffrin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">C. M. Ferrario</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Российский кардиологический журнал</subfield><subfield code="d">«FIRMA «SILICEA» LLC, 2019</subfield><subfield code="g">(2011), 4, Seite 102-108</subfield><subfield code="w">(DE-627)1760594547</subfield><subfield code="x">26187620</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2011</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:102-108</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/4b28ca57c7d64d6d819d4d1f90ad857e</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://russjcardiol.elpub.ru/jour/article/view/1131</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1560-4071</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2618-7620</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2011</subfield><subfield code="e">4</subfield><subfield code="h">102-108</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	H. Yokoyama
spellingShingle	H. Yokoyama misc RC666-701 misc atenolol misc cardiac hypertrophy misc hypertension misc olmesartan misc vascular remodelling misc Diseases of the circulatory (Cardiovascular) system ROLE OF BLOOD PRESSURE REDUCTION IN PREVENTION OF CARDIAC AND VASCULAR HYPERTROPHY
authorStr	H. Yokoyama
ppnlink_with_tag_str_mv	@@773@@(DE-627)1760594547
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC666-701
illustrated	Not Illustrated
issn	26187620
topic_title	RC666-701 ROLE OF BLOOD PRESSURE REDUCTION IN PREVENTION OF CARDIAC AND VASCULAR HYPERTROPHY atenolol cardiac hypertrophy hypertension olmesartan vascular remodelling
topic	misc RC666-701 misc atenolol misc cardiac hypertrophy misc hypertension misc olmesartan misc vascular remodelling misc Diseases of the circulatory (Cardiovascular) system
topic_unstemmed	misc RC666-701 misc atenolol misc cardiac hypertrophy misc hypertension misc olmesartan misc vascular remodelling misc Diseases of the circulatory (Cardiovascular) system
topic_browse	misc RC666-701 misc atenolol misc cardiac hypertrophy misc hypertension misc olmesartan misc vascular remodelling misc Diseases of the circulatory (Cardiovascular) system
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Российский кардиологический журнал
hierarchy_parent_id	1760594547
hierarchy_top_title	Российский кардиологический журнал
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)1760594547
title	ROLE OF BLOOD PRESSURE REDUCTION IN PREVENTION OF CARDIAC AND VASCULAR HYPERTROPHY
ctrlnum	(DE-627)DOAJ029443288 (DE-599)DOAJ4b28ca57c7d64d6d819d4d1f90ad857e
title_full	ROLE OF BLOOD PRESSURE REDUCTION IN PREVENTION OF CARDIAC AND VASCULAR HYPERTROPHY
author_sort	H. Yokoyama
journal	Российский кардиологический журнал
journalStr	Российский кардиологический журнал
callnumber-first-code	R
lang_code	rus
isOA_bool	true
recordtype	marc
publishDateSort	2011
contenttype_str_mv	txt
container_start_page	102
author_browse	H. Yokoyama D. B. Averill K. B. Brosnihan R. D. Smith E. L. Schiffrin C. M. Ferrario
class	RC666-701
format_se	Elektronische Aufsätze
author-letter	H. Yokoyama
author2-role	verfasserin
title_sort	role of blood pressure reduction in prevention of cardiac and vascular hypertrophy
callnumber	RC666-701
title_auth	ROLE OF BLOOD PRESSURE REDUCTION IN PREVENTION OF CARDIAC AND VASCULAR HYPERTROPHY
abstract	We investigated whether prevention of cardiac and vascular remodelling associated with inhibition of angiotensin II is independent of the blood pressure (BP) lowering action of angiotensin II type 1 (AT1) receptor blockade. Spontaneously hypertensive rats, 8 weeks old, were treated with olmesartan, atenolol, or vehicle in their drinking water for 56 days. At the end of each treatment, arterial pressure and heart rate were measured, the ratio of heart weight to body weight was calculated, collagen deposition in the heart was determined histochemically using picrosirius red staining, and wall-to-lumen ratio in isolated mesenteric arteries was measured by a video graphic approach. At 3 weeks after the initiation of treatment, rats medicated with olmesartan showed lower values of systolic BP compared with rats given atenolol or vehicle, whereas no difference in directly measured BP were observed at the end of study in anesthetized rats given olmesartan or atenolol. Rats given atenolol showed sustained bradycardia, whereas cardiac hypertrophy and collagen deposition was prevented only in spontaneously hypertensive rats given olmesartan. Olmesartan or atenolol reduced arteriolar wall-to-lumen ratio (olmesartan: 11,5±0,4%; atenolol: 13,3±0,6%; vehicle: 18,4%±1,1); however, this effect was greatest in rats medicated with the angiotensin II type 1 antagonist. Although control of BP is a factor in the prevention of cardiac and vascular hypertrophy, our studies suggest that blockade of angiotensin II receptors may attenuate the structural changes in the heart and blood vessels of hypertensive animals independent of a reduction in BP.
abstractGer	We investigated whether prevention of cardiac and vascular remodelling associated with inhibition of angiotensin II is independent of the blood pressure (BP) lowering action of angiotensin II type 1 (AT1) receptor blockade. Spontaneously hypertensive rats, 8 weeks old, were treated with olmesartan, atenolol, or vehicle in their drinking water for 56 days. At the end of each treatment, arterial pressure and heart rate were measured, the ratio of heart weight to body weight was calculated, collagen deposition in the heart was determined histochemically using picrosirius red staining, and wall-to-lumen ratio in isolated mesenteric arteries was measured by a video graphic approach. At 3 weeks after the initiation of treatment, rats medicated with olmesartan showed lower values of systolic BP compared with rats given atenolol or vehicle, whereas no difference in directly measured BP were observed at the end of study in anesthetized rats given olmesartan or atenolol. Rats given atenolol showed sustained bradycardia, whereas cardiac hypertrophy and collagen deposition was prevented only in spontaneously hypertensive rats given olmesartan. Olmesartan or atenolol reduced arteriolar wall-to-lumen ratio (olmesartan: 11,5±0,4%; atenolol: 13,3±0,6%; vehicle: 18,4%±1,1); however, this effect was greatest in rats medicated with the angiotensin II type 1 antagonist. Although control of BP is a factor in the prevention of cardiac and vascular hypertrophy, our studies suggest that blockade of angiotensin II receptors may attenuate the structural changes in the heart and blood vessels of hypertensive animals independent of a reduction in BP.
abstract_unstemmed	We investigated whether prevention of cardiac and vascular remodelling associated with inhibition of angiotensin II is independent of the blood pressure (BP) lowering action of angiotensin II type 1 (AT1) receptor blockade. Spontaneously hypertensive rats, 8 weeks old, were treated with olmesartan, atenolol, or vehicle in their drinking water for 56 days. At the end of each treatment, arterial pressure and heart rate were measured, the ratio of heart weight to body weight was calculated, collagen deposition in the heart was determined histochemically using picrosirius red staining, and wall-to-lumen ratio in isolated mesenteric arteries was measured by a video graphic approach. At 3 weeks after the initiation of treatment, rats medicated with olmesartan showed lower values of systolic BP compared with rats given atenolol or vehicle, whereas no difference in directly measured BP were observed at the end of study in anesthetized rats given olmesartan or atenolol. Rats given atenolol showed sustained bradycardia, whereas cardiac hypertrophy and collagen deposition was prevented only in spontaneously hypertensive rats given olmesartan. Olmesartan or atenolol reduced arteriolar wall-to-lumen ratio (olmesartan: 11,5±0,4%; atenolol: 13,3±0,6%; vehicle: 18,4%±1,1); however, this effect was greatest in rats medicated with the angiotensin II type 1 antagonist. Although control of BP is a factor in the prevention of cardiac and vascular hypertrophy, our studies suggest that blockade of angiotensin II receptors may attenuate the structural changes in the heart and blood vessels of hypertensive animals independent of a reduction in BP.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA
container_issue	4
title_short	ROLE OF BLOOD PRESSURE REDUCTION IN PREVENTION OF CARDIAC AND VASCULAR HYPERTROPHY
url	https://doaj.org/article/4b28ca57c7d64d6d819d4d1f90ad857e https://russjcardiol.elpub.ru/jour/article/view/1131 https://doaj.org/toc/1560-4071 https://doaj.org/toc/2618-7620
remote_bool	true
author2	D. B. Averill K. B. Brosnihan R. D. Smith E. L. Schiffrin C. M. Ferrario
author2Str	D. B. Averill K. B. Brosnihan R. D. Smith E. L. Schiffrin C. M. Ferrario
ppnlink	1760594547
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
callnumber-a	RC666-701
up_date	2024-07-03T22:54:59.907Z
_version_	1803600317559865344
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ029443288</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230501192743.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2011 xx \|\|\|\|\|o 00\| \|\|rus c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ029443288</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ4b28ca57c7d64d6d819d4d1f90ad857e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">H. Yokoyama</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">ROLE OF BLOOD PRESSURE REDUCTION IN PREVENTION OF CARDIAC AND VASCULAR HYPERTROPHY</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2011</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">We investigated whether prevention of cardiac and vascular remodelling associated with inhibition of angiotensin II is independent of the blood pressure (BP) lowering action of angiotensin II type 1 (AT1) receptor blockade. Spontaneously hypertensive rats, 8 weeks old, were treated with olmesartan, atenolol, or vehicle in their drinking water for 56 days. At the end of each treatment, arterial pressure and heart rate were measured, the ratio of heart weight to body weight was calculated, collagen deposition in the heart was determined histochemically using picrosirius red staining, and wall-to-lumen ratio in isolated mesenteric arteries was measured by a video graphic approach. At 3 weeks after the initiation of treatment, rats medicated with olmesartan showed lower values of systolic BP compared with rats given atenolol or vehicle, whereas no difference in directly measured BP were observed at the end of study in anesthetized rats given olmesartan or atenolol. Rats given atenolol showed sustained bradycardia, whereas cardiac hypertrophy and collagen deposition was prevented only in spontaneously hypertensive rats given olmesartan. Olmesartan or atenolol reduced arteriolar wall-to-lumen ratio (olmesartan: 11,5±0,4%; atenolol: 13,3±0,6%; vehicle: 18,4%±1,1); however, this effect was greatest in rats medicated with the angiotensin II type 1 antagonist. Although control of BP is a factor in the prevention of cardiac and vascular hypertrophy, our studies suggest that blockade of angiotensin II receptors may attenuate the structural changes in the heart and blood vessels of hypertensive animals independent of a reduction in BP.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">atenolol</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cardiac hypertrophy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hypertension</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">olmesartan</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">vascular remodelling</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">D. B. Averill</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">K. B. Brosnihan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">R. D. Smith</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E. L. Schiffrin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">C. M. Ferrario</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Российский кардиологический журнал</subfield><subfield code="d">«FIRMA «SILICEA» LLC, 2019</subfield><subfield code="g">(2011), 4, Seite 102-108</subfield><subfield code="w">(DE-627)1760594547</subfield><subfield code="x">26187620</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2011</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:102-108</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/4b28ca57c7d64d6d819d4d1f90ad857e</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://russjcardiol.elpub.ru/jour/article/view/1131</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1560-4071</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2618-7620</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2011</subfield><subfield code="e">4</subfield><subfield code="h">102-108</subfield></datafield></record></collection>
score	7.399455

Nicht das Richtige dabei?

Schreiben Sie uns!

ROLE OF BLOOD PRESSURE REDUCTION IN PREVENTION OF CARDIAC AND VASCULAR HYPERTROPHY

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?